A Randomized, Placebo-Controlled, 4-Period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Sitagliptin (Primary) ; Exendin 9
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 08 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History